

1. Us



Division of Clinical Pharmacology

Prof. Dr. med. Stefan Endres (director)
Tel. +49-(0)89-4400-5 7300, endres@lmu.de
Monika Fahrenkamp (office secretary)
Simone Gautier (project manager)
Dr. Katharina Dennemarck (project manager)

A Research Group: Immunopharmacology

Prof. Dr. med. Sebastian Kobold (head)
Tel. +49-(0)89-4400-5 7325
sebastian.kobold@med.uni-muenchen.de
Dr. med. Sophia Stock
Dr. rer. nat. Daria Briukhovetska (post-doc)
Dr. med. Adrian Gottschlich (post-doc)
Dr. rer. nat. Donjetë Simnica (postdoc)
Lisa Gregor, Ph. D.
Sebastijan Spajic, Ph. D.
Emanuele Carlini, Ph. D.
David Sanz, Ph. D.
Susanne Wenk (TA), Pedro Mesquita (TA),
Kaoutar Adjabi (TA)

B Research Group: Intracellular Immunity

Prof. Dr. med. Simon Rothenfusser (head)
Tel. +49-(0)89-4400-5 7321
simon.rothenfusser@med.uni-muenchen.de
Dr. rer. nat. Hadi Karimzadeh (post-doc)
Frank Dahlström (TA)

C Research Group: Cancer Vaccine Lab

Dr. rer. nat. Lars König (head)
Tel. +49-(0)89-4400-5 7322
lars.koenig@med.uni-muenchen.de
Prof. Dr. med. Maximilian Schnurr (head)
Tel. +49-(0)89-4400-5 7324
max.schnurr@med.uni-muenchen.de
Dr. med. Daniel Böhmer, (post-doc)
Dr. med. vet. Charlotte Marx, (post-doc)
Christine Hörth (TA)

D Research Group: Immunoregulation

(joint group with Departement of Gastroenterology)
Prof. Dr. med. David Anz (head)
Tel. +49-(0)89-4400-5 7331
david.anz@med.uni-muenchen.de
Dr. rer. nat. Carolin Perleberg (post-doc)
Jan Gärtig, M. Sc.
Patrick Layritz (TA)

2. Patient Care


A pharmacological consult service has been established at the Department of Medicine (Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Campus Innenstadt). In weekly rounds, staff members of the Division visit each out of nine medical wards. Questions on drug mechanisms, side effects and dosages are answered as a written consultation. In the area of pharmacogenetics assaying thiopurinemethyltransferase activity allows to identify patients at risk before initiating therapy with azathioprin. Prof. Endres and Prof. Schnurr, gastroenterologists, run an outpatient clinic focused on inflammatory bowel disease and viral hepatitis. Prof. Rothenfusser runs an out-patient clinic for adult patients with inborn immunodeficiency disorders.

3. Teaching

A lecture series on drug therapy in internal medicine (Arzneimitteltherapie in der Inneren Medizin) is organized each semester. Prof. Endres was course director of the Cardiovascular Course which has been performed twice yearly for each of the 228 medical students in the first clinical semester since winter 1997. This course became part of a reformed curriculum at the Medical Faculty of the University of Munich (Münchner Modell zum Medizinstudium, MeCuM^{LMU}) which has been initiated 2005 in close cooperation with Harvard Medical School.

4. Research


Prof. Endres serves as Dean of Research for the Medical Faculty of the LMU (fourth term 2017 to 2019). The division is speaker of the international doctoral program "i-Target: Immunotargeting of Cancer" (www.elitenetzwerk.bayern.de) awarded by the Elitenetzwerk Bayern and of the doctoral program "Immutrain training network for the immunotherapy of cancer". This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant. Research activities focus on two areas: First, the pharmacological regulation of inflammatory cytokine synthesis. Second, the cytokine- and cell-based therapy of gastrointestinal malignancies.



In the second area - the cytokine- and cell-based therapy of gastrointestinal tumors - an emphasis has been placed on the study and maturation of dendritic cells. An animal model of subcutaneous tumor development following injection of colon carcinoma cells has been established in mice.

5. Grants

BayImmuNet, Bayerisches Immuntherapie-Netzwerk



Bundesministerium für Bildung und Forschung (VIP plus)
Deutsche Forschungsgemeinschaft
Deutsche Krebshilfe
Elitenetzwerk Bayern (Doktorandenkolleg i-Target)
Else Kröner-Fresenius-Stiftung
Exzellenzinitiative des Bundes und der Länder
Friedrich Baur-Stiftung
Helmholtz Zentrum München (iMed-Initiative)
Horizon2020 of the EU
Studienstiftung des deutschen Volkes
Industry (4SC, TCR2 Cambridge, USA, Sanofi, Frankfurt)

In 2007 Prof. Endres was awarded an LMU research professorship of the German Excellence Initiative (0.9 Mio Euro) and became principal investigator in the Excellence Cluster Center for Integrated Protein Science Munich (CIPSSM). In 2016 PD Dr. Sebastian Kobold was selected for the career advancement award of the Ernst Jung Stiftung and PD Dr. med. Sebastian Kobold received the Vincenz-Czerny Award 2016 by the German Society for Hematology and Medical Oncology. In 2017 Sebastian Kobold received an ERC-starting grant with his project „ARMOR-T“ (1.6 Mio Euro).

6. Cooperations

Prof. Dr. Dr. Carole Bourquin, Universität Genf
Prof. Dr. Charles Dinarello, Department of Infectious Diseases,
University of Colorado, Denver, CO
PD Dr. Christian Klein, Glycart, Schlieren, CH
Prof. Dr. Hans-Anton Lehr, Pathology, Friedrichshafen
Prof. Dr. Eugene Maraskovsky, Ludwig Institute for Cancer Research,
Melbourne
Dr. Daniel Speiser, Ludwig Institute of Cancer Research, Lausanne
Dr. Claudio Sustmann, Roche AG
Prof. Dr. Ulrich von Andrian, Harvard Medical School
Prof. Dr. Kai W. Wucherpfennig, Dana-Farber Cancer Institute
Department of Cancer Immunology, Boston, USA

7. Original papers

Until 2014 (ten selected)

- Endres S**, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JWM, Cannon JG, Rogers TS, Klemperer MS, Weber PC, Schaefer EJ, Wolff SM, Dinarello CA. *The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells.* *New England Journal of Medicine* 1989; 320:265-71 (JIF 51.7)
- Hornung V, Guenther-Biller M, Bourquin C, Ablasser A, Schlee M**, Uematsu M, Manoharan M, Akira S, de Fougerolles A, **Endres S, Hartmann G**. *Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7.* *Nature Medicine* 2005; 11:263-70 (JIF 24.3)
- Hornung V, Ellegast J, Kim S**, Krzysztof Brzózka, Jung A, Kato H, **Poeck H**, Akira S, Conzelmann KK, **Schlee M, Endres S, Hartmann G**. *5' triphosphate RNA is the ligand for RIG-I.* *Science* 2006; 314:994-7 (JIF 30.0)
- Poeck H, Besch R, Maihoefer C**, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, **Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerdt T**, Berking C, **Bourquin C**, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Häcker G, Neuenhahn M, Busch D H, Rothenfusser S, Prinz M, Hornung V, **Endres S**, Tüting T, Hartmann G. *G 5'-triphosphate-siRNA: turning gene silencing and RIG-I activation against melanoma.* *Nature Medicine* 2008; 14:1256-63 (JIF 24.3)
- Gross O, Poeck H, **Bscheider M**, Dostert C, Hanneschläger N, **Endres S**, Tardivel A, Tschopp J, Ruland J. *Syk kinase signaling couples to the Nalp3 inflammasome for anti-fungal host defense.* *Nature* 2009; 459:433-6 (JIF 38.6)
- Besch R, Poeck H, Hohenauer T, Senft D, Häcker G, Berking C, Hornung V, **Endres S**, Ruzicka T, **Rothenfusser S**, Hartmann G. *Proapoptotic signalling by RIG-I and MDA-5 results in tumorspecific apoptosis independent of type I interferons in melanoma.* *Journal of Clinical Investigation* 2009; 119:2399-411 (JIF 12.8)
- Poeck H, **Bscheider M**, Gross O, Finger K, Roth S, Rebsamen M, Hanneschläger N, Schlee M, **Rothenfusser S**, Barchet W, Kato H, Akira S, Inoue S, **Endres S**, Peschel C, Hartmann G, Hornung V, Ruland J. *Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 β production.* *Nature Immunology* 2010; 11:63-9 (JIF 26.2)
- Dann A, **Poeck H**, Croxford AL, Gaupp S, Kierdorf K, Knust M, Pfeifer D, **Maihoefer C, Endres S**, Kalinke U, Meuth SG, Wiendl H, Knobloch KP, Akira S, Waisman A, Hartmann G, Prinz M. *Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS.* *Nature Neuroscience* 2012; 15:98-106 (JIF 15.3)
- Heidegger S*, Anz D*, Stephan N, Bohn B**, Herbst T, Fendler WP, **Suhartha N, Sandholzer N, Kobold S, Hotz C**, Eisenacher K, Radtke-Schuller S, **Endres S, Bourquin C**. *Virus-associated activation of innate immunity induces rapid disruption of Peyer's patches in mice. *diese Autoren leisteten gleichwertigen Beitrag* *Blood* 2013, 122:2591-9. (JIF 9.1)
- Hoffmann F, Schmidt A**, Dittmann Chevilotte M, **Wisskirchen C, Hellmuth JC, Willms S**, Gilmore RH, Glas J, Folwaczny M, Müller T, Berg T, Spengler U, Fitzmaurice K, Kelleher D, Reisch N, Rice CM, **Endres S, Rothenfusser S**. *Polymorphisms in MDA-5 link protein function to clearance of hepatitis C virus.* *Journal of Hepatology* 2014; 61:460-70. (JIF 10.4)

2015 to 2022 (selected)

- Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger J, Schnurr M, Rothenfußer S #**, *Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.* *The Journal of the National Cancer Institute* 2015, 107. (JIF 15.2)
* contributed equally to this study, # share senior authorship
- Geiger M, **Rataj F, Cadilha B, Lesch S, Heise C**, Murr R, vom Berg J, Jastroch M, Lamp D, Ding J, **Düwell P**, Niederfellner G, Sustmann C, **Endres S**, Klein Ch, **Kobold S**. *Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy.* *Clinical Cancer Research* 2019; 25:5890-5900. (JIF 10.2)
- Rapp M, Wintergerst M, Kunz W, Vetter V, Knott M, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S**, Meyer B, Röhrlé N, Piseddu I, Grassmann S, **Layritz P, Kühnemuth B**, Stutte S, Bourquin C, Andrian U, **Endres S, Anz D**. *CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.* *Journal of Experimental Medicine* 2019; 216:1170-1181. (JIF 10.8)
- Ruzicka M, König L, Formisano S, Boehmer D**, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhofer M, Ahlfeld J, **Kobold S, Endres S**, Subklewe M, **Düwell P, Schnurr M**, Jeremias I, Lichtenegger F, **Rothenfusser S**. *RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.* *Leukemia* 2020; 34:1017-1026. (JIF 9.9)
- Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B**, Dantes Z, **Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kuray M**, Larimer B, **Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Bennebarck MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö**, . . . **Rothenfusser S, Düwell P, Koenig L, Schnurr M**, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, **Endres S, Kobold S**. *T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours* *Nature Biomedical Engineering* 2021; 35:2243-2257. (JIF 20)
- Boehmer D, Formisano S**, de Oliveira Mann C, Mueller S, Kluge M, **Metzger P**, Rohlf M, **Hörth Ch, Kocheise L**, Lichtenthaler S, Hopfner KP, **Endres S, Rothenfusser S**, Friedel C, **Düwell P, Schnurr* M, Koenig* L**. *OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.* *Science Immunology* 2021; 61, eabe2550. (JIF 17.7)
- Scheck MK, Lehmann L, Zaucha M, Schwarzlmüller P**, Huber K, Pritsch M, Barba-Spaeth G, Thorn-Seshold O, Krug AB, **Endres S, Rothenfusser S**, Thorn-Seshold J. *FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.* *PLOS One* 2022; 17:e0262149. (JIF 3.2)



Division of Clinical Pharmacology

Medizinische Klinik und Poliklinik IV
Klinikum der Ludwig-Maximilians-Universität München
Campus Innenstadt
Lindwurmstraße 2a
80337 München

Tel.: +49-(0)89-4400-5-7300
Fax: +49-(0)89-4400-5-7330
Email: endres@lmu.de
Internet: www.klinische-pharmakologie.de